Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China , commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)- -Conference call
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021
DUBLIN, Ireland , July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , July 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
- Principal Repayments Delayed At Least Until January 1, 2022 - Repayment Delay and Recent ATM Activity Extends Cash Runway Substantially Through the First Quarter of 2022 DUBLIN, Ireland and FORT WASHINGTON, Pa. , June 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a
View HTML
Toggle Summary Nabriva Announces Changes to its Board of Directors
DUBLIN, Ireland and FORT WASHINGTON, Pa. , June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr.
View HTML
Toggle Summary Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland , June 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options
View HTML
Toggle Summary Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients treated with moxifloxacin Lefamulin was generally safe and
View HTML
Toggle Summary Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates
-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community- -Commenced exclusive distribution of SIVEXTRO in the U.S. on April 12, 2021 and moving forward will record 100% of net product
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com